Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same

Abstract

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production.

What is claimed is: 
     
         1 . A method for reducing sebum production in a subject in need thereof, the method comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition comprises about 0.1% to about 20 wt. % of DGLA, 15-HETrE and/or 15-OHEPA. 
     
     
         3 . The method of  claim 2 , wherein the pharmaceutical composition comprises about 1.65 wt. % steareth-2, about 1.35 wt. % steareth-21, about 0.5 wt. % cetyl alcohol, about 0.2 wt. % ascorbyl palmitate, about 0.15 wt. % a-tocopherol, about 2.0 wt. % medium-chain triglycerides (e.g., Crodamol GTCC), about 2.0 wt. % myristyl myristate, about 4.0 wt. % isopropyl palmitate, about 1.0 wt. % glycerin, about 1.0 wt. % phenoxyethanol, about 0.1 wt. % ascorbic acid, about 0.8 wt. % carbomer, about 0.4 wt. % xanthan gum, about 0.5 wt. % liquid soy lecithin, and about 0.05 wt. % Mild Care 345 fragrance. 
     
     
         4 . The method of  claim 2 , wherein the pharmaceutical composition comprising DGLA, 15-OHEPA, or 15-HETrE further includes a therapeutically effective amount of a retinoid analogue. 
     
     
         5 . The method of  claim 4 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue. 
     
     
         6 . The method of  claim 1 , wherein the step of administering comprises topically applying the composition to an area of the skin. 
     
     
         7 . The method of  claim 6 , wherein applying the composition results in about a 10%, 20%, 30%, 40%, 50% 60%, 70%, 80%, 90% or more reduction in an amount of sebum produced by the area of the skin. 
     
     
         8 . The method of  claim 6 , wherein the step of administering comprises topically applying the composition to an area of the skin afflicted with acne lesions. 
     
     
         9 . The method of  claim 8 , wherein the area of the skin afflicted with acne lesions is first washed prior to application of the pharmaceutical composition. 
     
     
         10 . The method of  claim 8 , wherein the acne lesions are inflammatory type and/or non-inflammatory type lesions. 
     
     
         11 . The method of  claim 10 , wherein the composition reduces about 10%, 20%, 30%, 40%, 50% 50%, 70%, 80%, 90% or more of the acne lesions. 
     
     
         12 . The method of  claim 1 , wherein the acne is associated with  Propionibacterium acnes.    
     
     
         13 . The method of  claim 1 , wherein the pharmaceutical composition is administered to the subject once a day, twice a day, or three times a day. 
     
     
         14 . The method of  claim 1 , wherein the pharmaceutical composition is a cream. 
     
     
         15 . The method of  claim 1 , wherein the subject previously exhibited acne lesions. 
     
     
         16 . The method of  claim 4 , wherein the retinoid analogue is adapalene. 
     
     
         17 . The method of  claim 16 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene. 
     
     
         18 . A product for use in the reduction of sebum production, the product comprising:
 (i) a container; and   (ii) a pharmaceutical composition comprising a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE, releasably confined inside the container.   
     
     
         19 . The product of  claim 18 , wherein the pharmaceutical composition comprises about 0.1% to about 20 wt. % of DGLA, 15-OHEPA, or 15-HETrE. 
     
     
         20 . The product of  claim 19 , wherein the pharmaceutical composition comprises about 1.65 wt. % steareth-2, about 1.35 wt. % steareth-21, about 0.5 wt. % cetyl alcohol, about 0.2 wt. % ascorbyl palmitate, about 0.15 wt. % a-tocopherol, about 2.0 wt. % medium-chain triglycerides (e.g., Crodamol GTCC), about 2.0 wt. % myristyl myristate, about 4.0 wt. % isopropyl palmitate, about 1.0 wt. % glycerin, about 1.0 wt. % phenoxyethanol, about 0.1 wt. % ascorbic acid, about 0.8 wt. % carbomer, about 0.4 wt. % xanthan gum, about 0.5 wt. % liquid soy lecithin, and about 0.05 wt. % Mild Care 345 fragrance. 
     
     
         21 . The product of  claim 18 , wherein the pharmaceutical composition comprising DGLA further includes a therapeutically effective amount of a retinoid analogue. 
     
     
         22 . The product of  claim 21 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue. 
     
     
         23 . The product of  claim 22 , wherein the retinoid analogue is adapalene. 
     
     
         24 . The product of  claim 23 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene. 
     
     
         25 . The product of  claim 18 , wherein the pharmaceutical composition comprising 15-OHEPA further includes a therapeutically effective amount of a retinoid analogue. 
     
     
         26 . The product of  claim 25 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue. 
     
     
         27 . The product of  claim 26 , wherein the retinoid analogue is adapalene. 
     
     
         28 . The product of  claim 27 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene. 
     
     
         29 . The product of  claim 18 , wherein the pharmaceutical composition comprising 15-HETrE further includes a therapeutically effective amount of a retinoid analogue. 
     
     
         30 . The product of  claim 29 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue. 
     
     
         31 . The product of  claim 30 , wherein the retinoid analogue is adapalene. 
     
     
         32 . The product of  claim 31 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene. 
     
     
         33 . A method for reducing the efficacious dose of an agent used in the reduction of sebum, the method comprising: adding a therapeutically effective amount of DGLA, 15-OHEPA, or 15-HETrE to the agent. 
     
     
         34 . The method of  claim 33 , wherein about 0.1% to about 20 wt. % of DGLA, 15-OHEPA, or 15-HETrE is added to the agent. 
     
     
         35 . The method of  claim 33 , wherein the agent is isotretinoin.